Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin

Authors

  • Jong-Lyel Roh MD, PhD,

    1. Department of Otolaryngology–Head and Neck Surgery, Cancer Research Institute, Chungnam National University College of Medicine, Daejeon, Korea
    Search for more papers by this author
  • Myung-Whun Sung MD, PhD,

    Corresponding author
    1. Departments of Otolaryngology–Head and Neck Surgery, Cancer Research Institute, and Clinical Research Institute, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, South Korea
    • Departments of Otolaryngology–Head and Neck Surgery, Cancer Research Institute, and Clinical Research Institute, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, South Korea
    Search for more papers by this author
  • Kwang Hyun Kim MD, PhD

    1. Departments of Otolaryngology–Head and Neck Surgery, Cancer Research Institute, and Clinical Research Institute, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, South Korea
    Search for more papers by this author

Abstract

Background.

Tumor growth is accelerated in surgical wounds. However, few experiments seeking to prevent such accelerated tumor growth have been performed.

Methods.

We created surgical wounds in three syngeneic mice for the implantation of three murine cancer cell lines, SCC VII, CT-26, and B16F10. The tumor growth in the wound group was compared with that in non-wound–control mice. Celecoxib or indomethacin was administered to the mice that had tumor implanted into the surgical wound to observe the tumor-suppressive effect.

Results.

The surgical wounds promoted tumor growth with different degrees, depending on the type of tumor. Such an accelerated tumor growth did not seem to be affected by cyclooxygenase-2 expression of tumors per se, but its mechanism needs to be explained by further studies. Celecoxib and indomethacin had a significant inhibitory effect on the tumor growth in the surgical wound. This suppressive effect is most obvious when celecoxib is administered daily from 1 day before surgical wounding and tumor implantation.

Conclusion.

Our results can justify that the preventive use of celecoxib in patients in whom local recurrence by tumor contamination is predicted. © 2005 Wiley Periodicals, Inc. Head Neck27: XXX–XXX, 2005

Ancillary